Sequoia, Google Ventures lead £20m series-A for Vaccitech

Neptune Ventures also took part in the financing, which brings the total raised by the company since inception to £30m.

Vaccitech will use the funding to expand its business and develop its laboratory structure, and to push its influenza and prostate cancer programmes through phase II testing by the end of 2019.

Company
Founded in a spin-out from Oxford University Innovation in 2016, Vaccitech is developing a universal influenza vaccine, which is in evaluation in a phase-IIb efficacy trial. It also develops a prostate cancer therapy currently at phase I, a Middle East Respiratory Syndrome (MERS) prophylactic, and Human Papillomavirus (HPV) and Hepatitis B therapies at the late pre-clinical stage.

People
Google Ventures – Tom Hulme (general partner).
Vaccitech – Tom Evans (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland
• Healthcare
• Venture
• United Kingdom